Trial
NCT01024842
Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Oxford
Collaborators
Medical Research Council
Condition
HIV-1
Intervention
MVA.HIVconsv low dose
Why stopped
Slow recruitment therefore study was stopped after 95% volunteers were enrolled.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-08